The Bulletin
Times Advertising


.

AIM Vaccine submitted the pre-application for clinical trials for novel-process highly-effective human diploid rabies vaccine

  • Written by The Bulletin

Achieve quality upgrade of traditional human diploid wild seedlings

HONG KONG SAR - Media OutReach Newswire - 27 March 2024 - AIM Vaccine Co., Ltd. (the "AIM Vaccine", together with its subsidiaries, the "Group") is pleased to announce that the Group has submitted the pre-application for clinical trials for novel-process highly-effective human diploid rabies vaccine on March 24, 2024.

Read more: AIM Vaccine submitted the pre-application for clinical trials for novel-process highly-effective...